BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 25048738)

  • 1. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.
    Kraemmer J; Kovacs GG; Perju-Dumbrava L; Pirker S; Traub-Weidinger T; Pirker W
    Mov Disord; 2014 Dec; 29(14):1767-73. PubMed ID: 25048738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
    Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
    Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson's disease.
    Honkanen EA; Saari L; Orte K; Gardberg M; Noponen T; Joutsa J; Kaasinen V
    Mov Disord; 2019 Oct; 34(10):1562-1566. PubMed ID: 31234224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias.
    Colloby SJ; McParland S; O'Brien JT; Attems J
    Brain; 2012 Sep; 135(Pt 9):2798-808. PubMed ID: 22961551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
    Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
    Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.
    O'Brien JT; Colloby S; Fenwick J; Williams ED; Firbank M; Burn D; Aarsland D; McKeith IG
    Arch Neurol; 2004 Jun; 61(6):919-25. PubMed ID: 15210531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia.
    Gil-Navarro S; Lomeña F; Cot A; Lladó A; Montagut N; Castellví M; Bosch B; Rami L; Antonell A; Balasa M; Pavia J; Iranzo A; Molinuevo JL; Sánchez-Valle R
    Eur J Neurol; 2013 Nov; 20(11):1459-e126. PubMed ID: 23679075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy.
    Perju-Dumbrava LD; Kovacs GG; Pirker S; Jellinger K; Hoffmann M; Asenbaum S; Pirker W
    Mov Disord; 2012 Jan; 27(1):65-71. PubMed ID: 22102521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease.
    Saari L; Kivinen K; Gardberg M; Joutsa J; Noponen T; Kaasinen V
    Neurology; 2017 Apr; 88(15):1461-1467. PubMed ID: 28283599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease.
    Weise D; Lorenz R; Schliesser M; Schirbel A; Reiners K; Classen J
    Mov Disord; 2009 Aug; 24(11):1669-75. PubMed ID: 19514075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.
    Jeon B; Kim JM; Jeong JM; Kim KM; Chang YS; Lee DS; Lee MC
    J Neurol Neurosurg Psychiatry; 1998 Jul; 65(1):60-4. PubMed ID: 9667562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation.
    Greco A; Zannetti A; Pappatà S; Albanese S; Coda AR; Ragucci M; Nardelli A; Brunetti A; Cuocolo A; Salvatore M
    Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):112-117. PubMed ID: 26329495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study.
    Ceravolo R; Volterrani D; Gambaccini G; Bernardini S; Rossi C; Logi C; Tognoni G; Manca G; Mariani G; Bonuccelli U; Murri L
    J Neural Transm (Vienna); 2004 Aug; 111(8):1065-73. PubMed ID: 15254794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.
    Martín-Bastida A; Lao-Kaim NP; Roussakis AA; Searle GE; Xing Y; Gunn RN; Schwarz ST; Barker RA; Auer DP; Piccini P
    Brain; 2019 Jul; 142(7):2023-2036. PubMed ID: 31056699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease.
    Andringa G; Drukarch B; Bol JG; de Bruin K; Sorman K; Habraken JB; Booij J
    Neuroimage; 2005 Jul; 26(4):1150-8. PubMed ID: 15908232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease.
    Alvarez-Fischer D; Blessmann G; Trosowski C; Béhé M; Schurrat T; Hartmann A; Behr TM; Oertel WH; Höglinger GU; Höffken H
    Neuroimage; 2007 Oct; 38(1):5-12. PubMed ID: 17716921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.